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Diseases of the abdominal aorta and its lower limb branches are common causes of leg pain, physical performance 
impairment and sudden  death1,2. Two common diagnoses are abdominal aortic aneurysm (AAA) and lower limb 
athero-thrombotic occlusive disease (peripheral artery disease; PAD)2,3. People commonly have both diagnoses, 
with approximately 40% of people with screen-detected AAA also having a diagnosis of  PAD4,5. Both PAD and 
AAA have been associated with impaired health-related quality of life (QOL)6–8. Whether people diagnosed 
with both AAA and PAD have worse QOL than those diagnosed with AAA alone is not known. It is important 
to clarify this, since if having diagnoses of both AAA and PAD is associated with worse QOL, this may support 
the value of adding screening for PAD to current AAA screening programs.
There are few medications that are effective in improving QOL of people diagnosed with either AAA or PAD. 
No drug has been demonstrated to improve QOL of people diagnosed with AAA 9. Only one current medication, 
cilostazol, is recommended by the  American10, but not the  European11, guidelines to treat the leg symptoms of 
PAD. Cilostazol has been reported to improve some but not all the domains of the short form (SF)-36 QOL 
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questionnaire in people with intermittent  claudication12,13. Effective medical treatments are needed to improve 
QOL in people diagnosed with PAD and AAA 9,14.
People diagnosed with  PAD15 or AAA 16 have microvascular dysfunction and this may contribute to impaired 
physical function and poor QOL. The degree of microvascular dysfunction is strongly correlated with the severity 
of  PAD15. Cilostazol is thought to work by increasing nitric oxide release and improving microvascular function, 
further supporting the importance of microvascular dysfunction in  PAD17. Fenofibrate is a peroxisome prolif-
erator-activated receptor α (PPARα) agonist used to treat  hypertriglyceridemia18. It has numerous pleiotropic 
effects, including upregulating nitric oxide  release19, which might improve QOL in people diagnosed with PAD 
or AAA. Fenofibrate has been reported to improve angiogenesis in animal models and reduce amputations in 
people with diabetes in a large clinical  trial20,21. It was therefore hypothesized that fenofibrate treatment would 
improve QOL in people that had been diagnosed with PAD and/ or AAA.
The current study had two aims. Aim one was to assess whether QOL was reduced in people diagnosed with 
both AAA and PAD in comparison to people that had between diagnosed with AAA alone or healthy controls. 
Aim two examined whether fenofibrate treatment for 24 weeks improved QOL of people diagnosed with AAA 
alone or both AAA and PAD.
Methods
Study design.  This study included both a case–control study and a secondary analysis of a randomized 
control trial. In the case–control study the QOL of participants diagnosed with both AAA and PAD was com-
pared to the QOL of participants diagnosed with AAA alone or the QOL of participants that had both an AAA 
and PAD excluded (healthy controls). In the second part of the study the effect of fenofibrate on the QOL of 
participants diagnosed with AAA was examined. The effect of fenofibrate was examined in all the participants 
diagnosed with AAA, whether or not they had concurrent PAD, but not the healthy controls who were excluded. 
This was a secondary analysis of the Fenofibrate in the Management of Abdominal Aortic Aneurysm (FAME) 2 
trial. The trial protocol and primary outcome analysis of the trial have been previously  published22,23. FAME-2 
was a multi-center, parallel, double-blind clinical trial in which people with a 35–49 mm AAA were randomly 
allocated to receive 145 mg fenofibrate or identical placebo for 24 weeks. People were excluded if AAA repair was 
already planned, they were already taking fenofibrate or they had a contra-indication to fenofibrate, including 
liver or renal impairment, previous reaction to fenofibrate or symptomatic gallbladder  disease22. This study was 
carried out according to protocols approved by the Prince Charles Hospital Human Research and Ethics Com-
mittee, the Royal Brisbane and Women’s Hospital Ethics Committee and the governance office of The Townsville 
Hospital and Health Services. The trial was registered with the Australian and New Zealand Clinical Trial Reg-
istry (ANZCTR12613001039774) prior to commencement. All participants provided written informed consent.
Participants.  Participants diagnosed with an AAA were recruited between the 12th October 2013 and the 
11th September 2015 from vascular surgery out-patient clinics in Brisbane, Gosford and Townsville, Australia. 
Twenty five healthy older control participants were recruited between 26th August 2016 and 23th May 2017. 
Healthy controls were aged ≥ 60 years, had no history of cardiovascular disease, including ischemic heart disease, 
stroke and PAD, or venous disease, and an ankle brachial pressure index (ABPI) of ≥ 0.90 but < 1.4 and no diag-
nosis of an AAA after an abdominal ultrasound scan (infra-renal aortic diameter < 30 mm).
Definitions, risk factors and medications.  PAD was defined by a documented history of prior periph-
eral revascularisation for chronic limb ischemia and/ or an ABPI < 0.90. Smoking history was classified as cur-
rent, former or never  smoker24. Hypertension, diabetes, ischemic heart disease, stroke and chronic airways dis-
ease were defined by a past documented history of diagnosis or treatment for these  conditions24. All prescribed 
medications were recorded at study entry. Heart rate and blood pressure was measured using a digital monitor, 
Omron Intellisense (HEM-907) after participants had rested for 15 min  supine25. Recordings were measured 
three times and averaged. Body mass index (BMI) and waist-hip ratio were measured as previously  described24. 
ABPI was measured in each lower limb using previously described methods and reported in each leg as the max-
imum of dorsalis pedis or posterior tibial divided by the maximum brachial pressure on either  side26. The infra-
renal aorta was imaged by ultrasound and maximum diameter measured in the anterior–posterior orthogonal 
plane from the outer adventitia to the outer adventitia by a single observer as previously  described23.
Health-related QOL.  The main outcome for this study was QOL assessed with the SF-36 questionnaire 
which was self-administered by each participant. Item responses for the SF-36 were recoded and summed for 
the health domain scores of physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), 
vitality (VT), social functioning (SF), role-emotional (RE) and mental health (MH)27. Scores were then trans-
formed using Australian SF-36 population norms to calculate norm-based (i.e. mean of 50, standard deviation 
of 10) scores with 0 (worst) and 100 (best) being the lowest and highest possible  scores27. Summary measures 
of physical (PCS) and mental components (MCS) were also calculated based on the 8 health domain  scores27.
Sample size.  The sample size for FAME-2 was planned to examine the effect of fenofibrate on two circulat-
ing biomarkers at 90% power, alpha 0.025 and allowing for a drop-out rate of 20%, as previously  reported23. It 
was estimated that 120 AAA participants were required. The sample size was expanded to 140 in order to mini-
mize the effect of any incomplete adherence to study drug. No a priori sample size calculation was performed 
to test the effect of fenofibrate on health-related QOL as a secondary outcome of FAME-222. Prior to analysis of 
the QOL data, however, a sample size estimate was performed. Minimal clinically important differences in SF-36 
domains for people with AAA or PAD have not been defined. For another chronic health problem (back pain) a 
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minimum clinically important difference has been estimated as 10.2% in the PCS of the SF-3628. In a prior study, 
mean (± standard deviation) results for the PCS were 36.9 ± 9.3 in 28 people with intermittent  claudication27. 
Using this mean and standard deviation for the control groups of the current study, a sample size of 18 per group 
would have a 90% power to detect a 10.2% difference in the PCS (alpha 0.05). Based on these estimates the cur-
rent study was adequately powered to test both aims.
Data analysis.  Nominal data were presented as number and percentage and were compared between groups 
using chi-squared test. Continuous data were not normally distributed according to the Shapiro–Wilk test and 
were presented as median and inter-quartile range and compared between groups using the Mann Whitney U 
test. To examine aim one, QOL domains measured with the SF-36 of participants diagnosed with both an AAA 
and PAD were separately compared with those of participants diagnosed with an AAA alone or healthy con-
trols, using Mann Whitney U tests. To examine aim 2, changes in QOL experienced by participants enrolled in 
the FAME2 trial were first assessed by comparing scores for the SF-36 domains at baseline to those at 24 weeks 
using the related samples Wilcoxon Signed Rank Test. The change in SF-36 QOL domains over 24 weeks were 
then compared between participants allocated to fenofibrate and placebo using Mann Whitney U tests. In a sub-
analysis, the change in SF-36 QOL domains over 24 weeks in participants that had been diagnosed with both an 
AAA and PAD were compared between those allocated to fenofibrate and placebo using the Mann Whitney U 
test. All analyses for aim 2 were based on intention to treat principles using all available data.
Table 1.  Baseline characteristics of participants in relation to diagnosis of abdominal aortic aneurysm and 
peripheral artery disease. AAA abdominal aortic aneurysm, PAD peripheral artery disease, ABPI ankle-
brachial pressure index. *Comparisons of participants who had both AAA and PAD diagnosed with those who 
had AAA but not PAD diagnosed were performed with chi-squared and Mann–Whitney U tests. †Comparison 
of participants who had both AAA and PAD diagnosed with those who had neither diagnosed were performed 
with chi-squared and Mann–Whitney U tests. ‡P < 0.05 for comparisons between participants with AAA but 
not PAD diagnosed and those with neither AAA nor PAD diagnosed. Missing from 1§ and 5‖ participants.
Characteristic AAA and PAD (n = 56) AAA no PAD (n = 84) P value* No AAA or PAD (n = 25) P value†
Age (years) 78 (72–81) 75 (70–80)‡ 0.232 70 (66–74) < 0.001
Men 46 (82.1%) 71 (84.5%) 0.710 17 (68.0%) 0.157
Smoking history 0.219 < 0.001
 Never 4 (7.1%) 14 (16.7%)‡ 14 (56.0%)
 Former 41 (73.2%) 58 (69.0%)‡ 11 (44.0%)
 Current 11 (19.6%) 12 (14.3%)‡ 0 (0.0%)
Years smoked 42 (26–54) 34 (20–49)‡ 0.019 0 (0–18) < 0.001
Average number of cigarettes 
per day 20 (10–25) 20 (10–25)‡ 0.794 0 (0–20) < 0.001
Hypertension 53 (94.6%) 77 (91.7%)‡ 0.503 12 (48.0%) < 0.001
Diabetes 20 (35.7%) 21 (25.0%)‡ 0.172 1 (4.0%) 0.003
Ischemic heart disease 29 (51.8%) 34 (40.5%)‡ 0.188 0 (0.0%) < 0.001
Previous stroke 12 (21.4%) 8 (9.5%) 0.049 0 (0.0%) 0.012
Chronic airways disease 19 (33.9%) 20 (23.8%) 0.191 5 (20.0%) 0.205
Medications
 Anti-coagulant 8 (14.3%) 11 (13.1%) 0.840 0 (0.0%) 0.047
 Calcium channel blocker 23 (41.1%) 25 (29.8%) 0.167 7 (28.0%) 0.260
 Furosemide 4 (7.1%) 2 (2.4%) 0.173 0 (0.0%) 0.171
 Other diuretic 12 (21.4%) 17 (20.2%) 0.865 2 (8.0%) 0.140
 Beta-blocker 22 (39.3%) 34 (40.5%) 0.888 5 (20.0%) 0.089
 ACE inhibitors 34 (60.7%) 39 (46.4%) 0.097 7 (28.0%) 0.007
 Angiotensin receptor blockers 20 (35.7%) 32 (38.1%)‡ 0.775 3 (12.0%) 0.029
 Any anti-platelet 41 (73.2%) 54 (64.3%)‡ 0.268 5 (20.0%) < 0.001
 Statin 47 (83.9%) 65 (77.4%)‡ 0.343 7 (28.0%) < 0.001
Body mass index (Kg/m2) 27.00 (23.00–31.00)§ 27.50 (24.00–32.00) 0.389 25.66 (23.75–29.54) 0.600
Waist-hip ratio 1.00 (0.95–1.04)§ 0.98 (0.92–1.02) 0.232 0.95 (0.89–1.03) 0.049
Left ABPI 0.90 (0.71–1.04) 1.07 (1.00–1.14)‡ < 0.001 1.15 (1.06–1.20) < 0.001
Right ABPI 0.86 (0.65–1.00) 1.06 (1.00–1.16)‡ < 0.001 1.14 (1.08–1.19) < 0.001
Systolic blood pressure (mmHg) 144 (133–153) 140 (127–152)‡ 0.109 123 (118–133) < 0.001
Diastolic blood pressure (mmHg) 75 (70–83) 77 (70–82) 0.774 76 (70–79) 0.806
Heart rate (beats per minute) 64 (58–71) 67 (60–72) 0.398 61 (59–70) 0.842
Infra-renal aortic diameter (mm) 39.9 (37.3–43.7) 39.2 (35.9–43.2) 0.433 18.2 (16.3–21.8)‖ < 0.001
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Results
comparison of participants that were diagnosed with both AAA and pAD and participants 
diagnosed  with  AAA  alone  or  healthy  controls.  Of the 140 participants diagnosed with AAA 
recruited, 56 (40%) also had PAD diagnosed. Of these 56 participants, 26 had PAD diagnosed based both on 
ABPI ≤ 0.90 and a prior history of PAD, 17 based on a prior history of PAD but a normal ABPI (0.91–1.20) and 
13 based on ABPI ≤ 0.90 alone. The 25 healthy controls had no prior history of cardiovascular disease, a normal 
ABPI and no AAA. Table 1 illustrates the risk factors of participants in relation to whether they had AAA or PAD 
diagnosed. Most risk factors were similar for participants diagnosed with both AAA and PAD in comparison 
to those diagnosed with AAA alone, except that people diagnosed with both AAA and PAD were significantly 
more likely to have a prior history of stroke and had a significantly lower ABPI (Table 1). In comparison with 
participants diagnosed with both AAA and PAD, or AAA alone, the healthy controls were significantly less likely 
to have a number of risk factors, such as a history of smoking, hypertension, diabetes, ischemic heart disease and 
stroke, and were significantly less commonly prescribed medications to treat hypertension, dyslipidemia and 
heart disease (Table 1). Table 2 illustrates the median and inter-quartile range for the domains of the SF-36 QOL 
questionnaires completed at entry. Participants diagnosed with both AAA and PAD had significantly poorer 
QOL scores for five of the ten domains of SF-36 by comparison to participants diagnosed with AAA alone 
(Table 2). Participants diagnosed with both AAA and PAD had significantly poorer QOL scores for seven of the 
ten domains of the SF-36 by comparison with the healthy controls (Table 2).  
Effect of fenofibrate on QOL and ABPI.  The 140 participants diagnosed with AAA, not the healthy con-
trols, were randomized to fenofibrate or placebo. One hundred and thirty seven of these 140 (98%) participants 
completed the 24 week FAME-2 study. There was one death and two withdrawals amongst the participants allo-
cated placebo (See Fig. 1)23. Pill counting suggested that 119 (85%) of participants took ≥ 80% of their medica-
tions, with no significant difference between  groups23. As previously reported, participants allocated fenofibrate 
had significantly lower serum triglyceride after 3 and 24 weeks in comparison to those allocated placebo and no 
excess of adverse  events23.
Over the 24 weeks of the study the participants had a small but significant decrease in median scores for two 
domains of the SF-36—the vitality (VT) and mental health (MH) domains (Table 3). No significant differences 
in the magnitude of change from baseline scores in any of the QOL domains were observed when comparing 
participants allocated fenofibrate or placebo (Table 4). These findings were similar whether all participants were 
analysed or just those diagnosed with both AAA and PAD (Table 4). Fenofibrate also had no effect on change 
in ABPI over 24 weeks (Table 4). 
Discussion
This study demonstrates that people diagnosed with both AAA and PAD have lower scores for several domains 
of the SF-36 by comparison to those diagnosed with AAA but not PAD. The study also found that, within a 
placebo-controlled randomized controlled trial, fenofibrate treatment for 24 weeks did not improve QOL or 
ABPI amongst participants diagnosed with AAA, whether or not they had concurrent PAD diagnosed.
International guidelines and systematic reviews recommend that patient-reported outcome measures 
receive greater  attention11,29. This study confirms that people diagnosed with AAA have worse QOL than 
healthy  controls8. Similar to previous studies, 40% of the participants diagnosed with AAA had concurrent PAD 
 diagnosed4,5. QOL was worse in participants that had diagnoses of both PAD and AAA than in those that had 
a diagnosis of AAA alone. One possible explanation for this could be the greater co-morbidities in participants 
Table 2.  Comparison of the health-related quality of life of participants in relation to the diagnosis of 
abdominal aortic aneurysm and lower limb peripheral artery disease. Shown are median (inter-quartile range) 
scores for the different domains of the Short-Form 36 questionnaire. *Comparisons of participants who had 
both AAA and PAD diagnosed with those who had AAA but not PAD diagnosed were performed with chi-
squared and Mann–Whitney U tests. †Comparison of participants who had both AAA and PAD diagnosed 
with those who had neither diagnosed were performed with chi-squared and Mann–Whitney U tests. ‡P < 0.05 
for comparisons between participants with AAA but not PAD diagnosed and those with neither AAA nor PAD 
diagnosed. AAA abdominal aortic aneurysm, PAD peripheral artery disease.
Short-form 36 domain AAA and PAD AAA no PAD P value* No AAA or PAD P value†
Physical functioning 37 (32–48) 49 (38–53) < 0.001 51 (46–53) < 0.001
Role physical 48 (41–54) 52 (42–56) 0.024 54 (50–56) 0.011
Bodily pain 44 (36–59) 48 (40–59) 0.354 53 (46–59) 0.241
General health 44 (32–51) 50 (39–55) 0.003 50 (46–56) 0.001
Vitality 47 (37–55) 52 (43–55)‡ 0.039 55 (49–58) 0.001
Social functioning 57 (45–57) 57 (51–57)‡ 0.154 57 (57–57) 0.016
Role emotional 55 (47–55) 55 (47–55)‡ 0.328 55 (51–55) < 0.001
Mental health 55 (46–58) 58 (49–60) 0.101 58 (49–61) 0.276
Physical component summary 41 (32–48) 48 (37–53)‡ 0.002 51 (48–55) < 0.001
Mental component summary 56 (50–60) 57 (51–61) 0.572 58 (53–61) 0.363
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with both vascular problems. Prior history of stroke, but not other co-morbidities, such as chronic airways disease 
and ischemic heart disease, was more common in participants that had diagnoses of both lower PAD and AAA 
by comparison to those that just had a diagnosis of AAA. It is possible that this difference contributed to the 
poorer physical aspects of QOL in participants diagnosed with both vascular conditions. More likely, though, 
is that the established effect of leg ischemia to cause pain and reduce physical performance was responsible for 
the differences in QOL  demonstrated7,8. People diagnosed with both AAA and PAD are also substantially more 
likely to have a cardiovascular event, with a recent study reporting that those with concurrent PAD had about 
a threefold higher rate of major cardiovascular events than those diagnosed with AAA  alone30. Given the high 
prevalence, worse QOL and increased cardiovascular event rate associated with concurrent PAD amongst people 
diagnosed with AAA, there is a good case for screening for low ABPI or absent pulses amongst people identi-
fied to have AAA, although this is not currently recommended in European  guidelines11,31. Diagnosis of PAD 
would enable additional treatment, such as supervised exercise therapy, to be provided aimed at improving QOL.
Prior animal and clinical observational studies suggest that fenofibrate has potential to improve QOL amongst 
people diagnosed with PAD and/or AAA 15–17,19–21. This study, however, found no evidence of benefit of fenofibrate 
Figure 1.  Illustration of the participant flow in the FAME-2 trial as previously  published23.
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Table 3.  Comparison of the health-related quality of life of participants enrolled in the FAME-2 trial at 
baseline and 24 weeks. Shown are median (inter-quartile range) scores for the different domains of the Short-
Form 36 questionnaire. *P values were generated using the related samples Wilcoxon Signed Rank test.
Short-form 36 domain Baseline 24 weeks P value*
Physical functioning 44 (33–51) 44 (31–51) 0.469
Role physical 50 (41–56) 52 (41–56) 0.371
Bodily pain 46 (36–59) 48 (36–53) 0.471
General health 48 (37–55) 48 (35–53) 0.250
Vitality 49 (43–55) 46 (40–52) 0.014
Social functioning 57 (51–57) 57 (48–57) 0.730
Role emotional 55 (47–55) 55 (47–55) 0.444
Mental health 55 (49–58) 55 (46–58) 0.025
Physical component summary 44 (35–51) 44 (35–51) 0.993
Mental component summary 57 (51–60) 56 (49–60) 0.050
Table 4.  Comparison of change in the health-related quality of life of participants allocated fenofibrate or 
placebo over 24 weeks. Shown are median (inter-quartile range) changes in scores for different domains of the 
Short-Form 36 questionnaire over 24 weeks. Three participants diagnosed with both AAA and PAD allocated 
to placebo were lost to follow-up and did not complete SF-36 assessments at 24 weeks. In some participants 
ABPI could not be measured due to incompressible arteries and thus assessment were limited to †65, *66, ‡68, 




P valuesFenofibrate (n = 70) Placebo (n = 67)
Physical functioning 0 (− 4 to 4) 0 (− 4 to 4) 0.566
Role physical 0 (− 2 to 4) 0 (− 2 to 4) 0.714
Bodily pain 0 (− 8 to 4) 0 (− 4 to 5) 0.061
General health 0 (− 2 to 5) 0 (− 7 to 2) 0.166
Vitality 0 (− 6 to 3) 0 (− 6 to 3) 0.965
Social functioning 0 (0 to 0) 0 (0 to 0) 0.776
Role emotional 0 (− 6 to 0) 0 (− 3 to 5) 0.511
Mental health 0 (− 6 to 3) 0 (− 6 to 3) 0.718
Physical component summary − 1 (− 4 to 3) 0 (− 4 to 4) 0.532
Mental component summary 0 (− 5 to 2) − 1 (− 6 to 3) 0.880
Haemodynamic outcomes
Percentage change in left ankle-brachial pressure index − 0.9 (− 5.3 to 1.3)‡ − 0.7 (− 6.7 to 3.2)* 0.927
Percentage change in right ankle-brachial pressure index − 1.0 (− 7.9 to 2.2)‡ − 0.4 (− 6.1 to 4.7)† 0.406
Participants diagnosed with both AAA and PAD
Short-Form 36 domain
Drug allocation
P valuesFenofibrate (n = 24) Placebo (n = 29)
Physical functioning 1 (− 2 to 4) 2 (− 1 to 6) 0.346
Role physical 0 (0 to 5) 0 (− 4 to 4) 0.349
Bodily pain − 2 (− 8 to 3) 0 (− 4 to 6) 0.142
General health − 1 (− 5 to 3) 0 (− 4 to 3) 0.529
Vitality − 5 (− 9 to 3) 0 (− 6 to 5) 0.285
Social functioning 0 (− 6 to 0) 0 (− 3 to 6) 0.342
Role emotional 0 (− 4 to 0) 0 (0 to 8) 0.196
Mental health − 1 (− 9 to 0) 0 (− 6 to 4) 0.068
Physical component summary 0 (− 3 to 4) 0 (− 5 to 4) 0.915
Mental component summary − 1 (− 7 to 1) 1 (− 5 to 4) 0.174
Haemodynamic outcomes
Percentage change in left ankle-brachial pressure index change − 0.8 (− 3.2 to 0.6)§ 0.2 (− 5.7 to 3.5)‖ 0.612
Percentage change in right ankle-brachial pressure index change 0.1 (− 6.2 to 11.8)§ − 1.6 (− 6.6 to 1.9)‖ 0.352
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on aspects of QOL assessed by the SF-36 in participants diagnosed with AAA alone or both AAA and PAD. 
Fenofibrate also had no effect on ABPI over 24 weeks. These findings do not favour further investigation of 
fenofibrate as a medication to improve QOL in people diagnosed with AAA.
The findings of this study should be interpreted after considering the strengths and weaknesses of the inves-
tigation. This was the first study, as far as the investigators are aware, to compare QOL in people diagnosed with 
both AAA and PAD to those diagnosed with AAA alone. The sample sizes included were small and the general-
izability of the findings needs to be more widely examined. Also assessment of QOL was limited to the generic 
SF-36. While this is a commonly used measure, a number of new patient reported outcome assessments have now 
been developed for people diagnosed with AAA but these were not available for the current  study32. In testing 
the effect of fenofibrate on QOL an important strength was the randomized placebo-controlled design. Blinding 
of participants and investigators was maintained throughout. Adherence to study medication was good and loss 
to follow-up low. Important weaknesses included that QOL was a secondary outcome of FAME-2 and thus no 
a priori sample size estimate was performed. While the posthoc sample size estimate suggested the study was 
adequately powered, it remains possible, particular in the sub-analysis of people diagnosed with both AAA and 
PAD, that the study was underpowered. Also no objective assessment of physical performance was performed. 
This investigation therefore does not rule out a moderate effect of fenofibrate in improving (or reducing) QOL 
in people with PAD and/or AAA. It should also be acknowledged that this was a secondary analysis of a trial for 
which the primary outcome analysis was negative and therefore the findings need to be interpreted as exploratory.
In conclusion, this study suggests that amongst people diagnosed with a small AAA, those who also had a 
concurrent diagnosis of PAD had the worst health-related QOL. The study also found no benefit of fenofibrate 
in improving QOL in people diagnosed with a small AAA, irrespective of whether they had concurrent PAD 
diagnosed.
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